Acquisition strengthens Regeneron’s innovative portfolio of immuno-oncology candidates and diversified approach to cancer treatment TARRYTOWN, N.Y. , May 31, 2022 /PRNewswire/ —  Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced that it has successfully acquired Checkmate

Original Source

On

Related Post


Notice: ob_end_flush(): failed to send buffer of zlib output compression (0) in /home/biznews/public_html/wp-includes/functions.php on line 5219